Skip to main content
Sign In
 

Mental / Behavioral / Developmental Health


 

The World Health Organization reported that mental illness accounts for over 15% of the burden of disease in developed countries. Mental health disorders, like anxiety and depression, can co-concur with alcohol and substance abuse which affects academic and life functioning and socioeconomic status in adulthood. Mental disorders in children can often be severe and persistent. Medical expenditures for the treatment of childhood mental disorders is higher than all other children’s health conditions.

Dr. Elaine Morrato is focusing on the adoption of drug safety recommendations into clinical practice. In 2007, she had eight publications in this area and currently is leading research evaluating the adoption of diabetes screening recommendations for patients taking second-generation antipsychotics. COR’s drug safety research will receive a big boost from a new AHRQ grant to COHO that has pediatric components. Drs. Bunik and Stafford are evaluating a program that has been implemented at the pediatric clinic at The Children’s Hospital involving co-location of psychiatric services within pediatric primary care practice. In addition to evaluating the effectiveness of the program on patient outcomes, COR researchers are also evaluating the effectiveness of this delivery model on teaching residents about psychiatric issues.

Current Grants

CORNET Continuity Clinic Research Network, Integrated Mental Health in Teaching Settings, Survey of Continuity Clinic Directors
Primary Investigator: Maya Bunik, MD, MSPH
Funding Agency: Dr. Doug Jones Internal funding
Amount: $10,000
Term: 2009-2010

Abstracts

Bunik M, Talmi A, Rannie M, Asherin R, Beaty B, Watlington T. Post-partum Depression Screening and Assistance: makings for a Medical Home. Submitted for presentation at the Pediatric Academic Society Annual Meeting. May, 2010. Vancouver, BC

Bunik M, Talmi A, Rannie M, Asherin R, Beaty B, Watlington T. Ages and Stages Screening in a Teaching Setting: Identification, Referral and Evaluation. Submitted for presentation at the Pediatric Academic Society Annual Meeting. May, 2010. Vancouver, BC

Morrato EH, Druss B, Hartung DM, Valuck RJ, Thomas D, Allen RR, Campagna E, Newcomer JW. Determinants of metabolic testing for patients treated with second-generation antipsychotics after the FDA diabetes Warning. Oral presentation at the 25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI, August 16-19, 2009. Pharmacoepidemiology and Drug Safety. 2009.

Morrato EH, Druss, B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic testing rates in three state Medicaid programs after FDA Warnings on Antipsychotic Drugs and Diabetes. Poster presentation at the 2009 APA Annual Meeting, San Francisco, CA, May 16-19, 2009.

Morrato EH, Nicol G, Druss B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic risk mitigation in children receiving antipsychotics. Poster presentation at the 25th Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI, August 16-19, 2009. Pharmacoepidemiology and Drug Safety. 2009.

Presentations

Bunik M, Co-Chair Hot Topic Workshop Session on Integrated Mental Health Care in Teaching Setting with Johns Hopkins and University of Rochester, NY at the Pediatric Academic Society Annual Meeting. May, 2010. Vancouver, BC

Morrato EH. Influences of Individual and Geographic Factors on Drug Safety Practices: Applications for Antipsychotics and Diabetes Risk, Colorado Health Outcomes Methods and Applications Seminar, University of Colorado Denver, Aurora, CO (January 2009).

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Impact of the atypical antipsychotic FDA Warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. NCDEU CME Poster Session 2008. Best research posters presented at the 2008 NCDEU (New Clinical Drug Evaluation Unit) Meeting. CME Institute, Physicians Postgraduate Press, Inc., The Journal of Clinical Psychiatry (October 2008)

Morrato EH, Nicol GE, Druss BG, Hartung DM, Valuck RJ, Allen RR, Campagna E, and Newcomer JW. Metabolic Risk Mitigation in Children Receiving Antipsychotics. Poster presentation at the 2009 Quality, Patient Safety and Clinical Informatics Poster Session, The Children’s Hospital, 10-16-2009

Publications

Banta JE, Morrato EH, Lee SW, Haviland MG. Retrospective Analysis of Diabetes Care in California Medicaid Patients with Mental Illness Journal of General Internal Medicine. May 5 2009 [Epub ahead of print]

Morrato EH, Cuffel B, Newcomer JW, Lombard I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients. Journal of Clinical Psychopharmacology; 2009; 29(1): 26-32.

Morrato EH, Druss, B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic testing rates in three state Medicaid programs after FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. Arch Gen Psych

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the ADA’s Statement on antipsychotic drugs and diabetes Diabetes Care 2009; 32(6): 1037-1042.

Morrato EH, Nicol G, Maahs D, Druss B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic risk monitoring in children receiving second-generation antipsychotic drugs Arch Ped and Adolesc Med

Morrato EH, Druss B, Hartung DM, Valuck RJ, Thomas D, Allen RR, Campagna E, Newcomer JW. Small Area Variation in Metabolic Risk Management for Patients Initiating Second-Generation Antipsychotics (under review: Pharmacoepidemiology and Drug Safety).